Elad Asher: What Should a Patient Take after Left Atrial Appendage Occlusion?
Elad Asher, Interventional cardiologist, Head of ICCU, Deputy Director of the Heart Center at SZMC, and Associate Professor of Cardiology at the Hebrew University of Jerusalem, shared a post on LinkedIn about a recent article by Laurent Fauchier et al., published in EuroIntervention, adding:
“What should a patient take after left atrial appendage occlusion?
The device trials answered with their own protocols, and practice has drifted toward simpler regimens without much comparative evidence. A propensity-matched analysis in EuroIntervention by Laurent Fauchier, Gregory Lip and colleagues is the largest comparison so far.
Using the TriNetX Global Network, the authors identified adults with atrial fibrillation who underwent percutaneous LAAO between 2010 and 2025 and built three parallel propensity score-matched comparisons: reduced-dose DOAC versus dual antiplatelet therapy, single antiplatelet versus dual, and reduced-dose DOAC versus single antiplatelet.
In the main comparison, 1,773 patients per group, mean follow-up 1.4 years, reduced-dose DOAC was associated with lower all-cause death (hazard ratio 0.79, 95% confidence interval 0.65 to 0.96) and less major bleeding (0.87, 0.77 to 0.98), with no significant difference in ischaemic stroke, thromboembolism or device-related thrombosis. Net clinical benefit favoured the DOAC (0.87, 0.78 to 0.96).
Single antiplatelet therapy also bled less than dual therapy. Against single antiplatelet therapy, however, 1,582 per group, reduced-dose DOAC showed a non-significant trend toward more major bleeding (1.14, 1.00 to 1.30, p=0.06) and no difference in mortality, thromboembolic outcomes or net clinical benefit.
The authors’ conclusion is measured: reduced-dose DOAC looked more favourable than DAPT but showed no clear advantage over SAPT, which supports simplified and individualised post-implantation strategies.
Limitations: electronic health record data, not a trial. Matching cannot remove the reasons a clinician chose a DOAC over antiplatelets, follow-up is short, and the abstract gives no absolute event rates, so the hazard ratios cannot be turned into numbers needed to treat.
What this means in practice: it does not license a new default. It does make dual antiplatelet therapy the regimen that now has the least support in comparative data, and it puts single antiplatelet and reduced-dose DOAC side by side as the candidates a randomised trial should compare.
What do you discharge your LAAO patients on today, and what would change your mind?”
Title: Reduced-dose direct oral anticoagulant versus antiplatelet strategies after left atrial appendage occlusion
Authors: Laurent Fauchier, Mathieu Nasarre, Bertrand Pierre, Arnaud Bisson, Gregory Y.H. Lip
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 19, 2026, 01:53Thomas Dayspring: Understanding Genome and Lipid Interactions in Lipidology
-
Sep 19, 2026, 01:47Abdurrahman Tufan: Combination Targeted Therapy in Refractory Systemic Autoinflammatory Diseases
-
Sep 19, 2026, 01:44Patrick James Lynch: Mother of a Thousand Sons Premieres at BDC 2026
-
Sep 19, 2026, 01:41Genetic Fate Mapping Reveals Endothelial Cells During Venous Thrombus Resolution – RPTH Journal
-
Sep 19, 2026, 01:39Mostafa Hammam: Three Different Platelet Defects – One Common Symptom
-
Sep 19, 2026, 01:38Jeff Sternlicht: A Heart Attack Should Not Be the Starting Line
-
Sep 19, 2026, 01:28Luis Oliverio Ambriz Garcia: Key Points From the ASH 2026 Guidelines on Iron Deficiency
-
Sep 19, 2026, 01:27Farjah Algahtani: A New Era in the Treatment of Transfusion-Dependent Thalassaemia
-
Sep 19, 2026, 01:24Aravind Palraj: 2025 EULAR Behçet’s Syndrome Update – 5 Practical Take-Home Points